Xiaolin Zhu, MD, PhD

Xiaolin Zhu, MD, PhD

Adjunct Instructor, Department of Medicine, UCSF

Cancer Center Program Membership

Prostate Cancer

550 16th Street, #6666
San Francisco, CA 94158

UCSF Profiles

Research Funding

  • July 1, 2024 - July 1, 2028 - Investigating SSTR1 as a novel biomarker and therapeutic target in advanced prostate cancer , Principal Investigator . Sponsor: Department of Defense, Sponsor Award ID: PC230021
  • November 1, 2022 - November 1, 2025 - Investigating SSTR1 in acquired resistance to androgen receptor signaling inhibitors in advanced prostate cancer , Principal Investigator . Sponsor: Prostate Cancer Foundation, Sponsor Award ID: 22YOUN07
  • July 1, 2022 - June 30, 2023 - Integrated Genomic Profiling to Define Acquired Resistance Mechanisms to Androgen Receptor Signaling Inhibition in Metastatic Castration-Resistant Prostate Cancer , Principal Investigator . Sponsor: Conquer Cancer, the ASCO Foundation, Sponsor Award ID: 139208A

Education

Fellowship, 06/2024 - Hematology/Oncology, UCSF
Residency, 06/2020 - Internal Medicine, UT Southwestern Medical Center
PhD, 06/2017 - Genetics and Genomics, Duke University
Bachelor of Medicine (MD equivalent), 06/2011 - Clinical Medicine, Shanghai Jiao Tong University School of Medicine

Honors & Awards

  • Physician Research Award, Department of Defense, 2024-2028
  • PCF Young Investigator Award, Prostate Cancer Foundation, 2022-2025
  • ASCO Young Investigator Award, Conquer Cancer, the ASCO Foundation, 2022-2023

Selected Publications

  1. Zhu X, Chan E, Turski ML, Mendez CE, Hsu SC, Kumar V, Shipp C, Jindal T, Chang K, Onodera C, Devine WP, Grenert JP, Stohr BA, Ding CC, Stachler MD, Quigley DA, Feng FY, Chu CE, Porten SP, Chou J, Friedlander TW, Koshkin VS. HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains. Oncologist. 2024 Aug 05; 29(8):e1094-e1097.  View on PubMed
  2. Shrestha R, Chesner LN, Zhang M, Zhou S, Foye A, Lundberg A, Weinstein AS, Sjöström M, Zhu X, Moreno-Rodriguez T, Li H, SU2C/PCF West Coast Prostate Cancer Dream Team, Alumkal JJ, Aggarwal R, Small EJ, Lupien M, Quigley DA, Feng FY. An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression. Cancer Res. 2024 Sep 16; 84(18):3086-3100.  View on PubMed
  3. Zhu X, Koshkin VS. Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer. Med. 2024 Feb 09; 5(2):106-108.  View on PubMed
  4. Lundberg A, Zhang M, Aggarwal R, Li H, Zhang L, Foye A, Sjöström M, Chou J, Chang K, Moreno-Rodriguez T, Shrestha R, Baskin A, Zhu X, Weinstein AS, Younger N, Alumkal JJ, Beer TM, Chi KN, Evans CP, Gleave M, Lara PN, Reiter RE, Rettig MB, Witte ON, Wyatt AW, Feng FY, Small EJ, Quigley DA. The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer. Cancer Res. 2023 08 15; 83(16):2763-2774.  View on PubMed
  5. Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal R, Small EJ, Fong L, Chou J, Friedlander T, de Kouchkovsky I, Koshkin VS. Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin. Clin Genitourin Cancer. 2023 10; 21(5):e394-e404.  View on PubMed
  6. Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou J, Friedlander T, Koshkin VS. Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer. Front Oncol. 2023; 13:1161089.  View on PubMed
  7. Alkelai A, Greenbaum L, Heinzen EL, Baugh EH, Teitelbaum A, Zhu X, Strous RD, Tatarskyy P, Zai CC, Tiwari AK, Tampakeras M, Freeman N, Müller DJ, Voineskos AN, Lieberman JA, Delaney SL, Meltzer HY, Remington G, Kennedy JL, Pulver AE, Peabody EP, Levy DL, Lerer B. New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach. Prog Neuropsychopharmacol Biol Psychiatry. 2019 08 30; 94:109659.  View on PubMed
  8. McCormack M, McGinty RN, Zhu X, Slattery L, Heinzen EL, EPIGEN Consortium, Costello DJ, Delanty N, Cavalleri GL. De-novo mutations in patients with chronic ultra-refractory epilepsy with onset after age five years. Eur J Med Genet. 2020 Jan; 63(1):103625.  View on PubMed
  9. Petrovski S, Aggarwal V, Giordano JL, Stosic M, Wou K, Bier L, Spiegel E, Brennan K, Stong N, Jobanputra V, Ren Z, Zhu X, Mebane C, Nahum O, Wang Q, Kamalakaran S, Malone C, Anyane-Yeboa K, Miller R, Levy B, Goldstein DB, Wapner RJ. Whole-exome sequencing in the evaluation of fetal structural anomalies: a prospective cohort study. Lancet. 2019 02 23; 393(10173):758-767.  View on PubMed
  10. Zhu X. Mutation Clearance after Transplantation for Myelodysplastic Syndrome. N Engl J Med. 2018 12 13; 379(24):2379-2380.  View on PubMed
  11. Heinzen EL, O'Neill AC, Zhu X, Allen AS, Bahlo M, Chelly J, Chen MH, Dobyns WB, Freytag S, Guerrini R, Leventer RJ, Poduri A, Robertson SP, Walsh CA, Zhang M, Epi4K Consortium, Epilepsy Phenome/Genome Project. De novo and inherited private variants in MAP1B in periventricular nodular heterotopia. PLoS Genet. 2018 05; 14(5):e1007281.  View on PubMed
  12. Zhu X, Padmanabhan R, Copeland B, Bridgers J, Ren Z, Kamalakaran S, O'Driscoll-Collins A, Berkovic SF, Scheffer IE, Poduri A, Mei D, Guerrini R, Lowenstein DH, Allen AS, Heinzen EL, Goldstein DB. A case-control collapsing analysis identifies epilepsy genes implicated in trio sequencing studies focused on de novo mutations. PLoS Genet. 2017 Nov; 13(11):e1007104.  View on PubMed
  13. Mori M, Haskell G, Kazi Z, Zhu X, DeArmey SM, Goldstein JL, Bali D, Rehder C, Cirulli ET, Kishnani PS. Sensitivity of whole exome sequencing in detecting infantile- and late-onset Pompe disease. Mol Genet Metab. 2017 12; 122(4):189-197.  View on PubMed
  14. Petrovski S, Küry S, Myers CT, Anyane-Yeboa K, Cogné B, Bialer M, Xia F, Hemati P, Riviello J, Mehaffey M, Besnard T, Becraft E, Wadley A, Politi AR, Colombo S, Zhu X, Ren Z, Andrews I, Dudding-Byth T, Schneider AL, Wallace G, University of Washington Center for Mendelian Genomics, Rosen ABI, Schelley S, Enns GM, Corre P, Dalton J, Mercier S, Latypova X, Schmitt S, Guzman E, Moore C, Bier L, Heinzen EL, Karachunski P, Shur N, Grebe T, Basinger A, Nguyen JM, Bézieau S, Wierenga K, Bernstein JA, Scheffer IE, Rosenfeld JA, Mefford HC, Isidor B, Goldstein DB. Germline De Novo Mutations in GNB1 Cause Severe Neurodevelopmental Disability, Hypotonia, and Seizures. Am J Hum Genet. 2016 05 05; 98(5):1001-1010.  View on PubMed
  15. Liu Y, Liu J, Lu J, Peng J, Juan L, Zhu X, Li B, Wang Y. Joint detection of copy number variations in parent-offspring trios. Bioinformatics. 2016 04 15; 32(8):1130-7.  View on PubMed
  16. Zhu X, Petrovski S, Xie P, Ruzzo EK, Lu YF, McSweeney KM, Ben-Zeev B, Nissenkorn A, Anikster Y, Oz-Levi D, Dhindsa RS, Hitomi Y, Schoch K, Spillmann RC, Heimer G, Marek-Yagel D, Tzadok M, Han Y, Worley G, Goldstein J, Jiang YH, Lancet D, Pras E, Shashi V, McHale D, Need AC, Goldstein DB. Whole-exome sequencing in undiagnosed genetic diseases: interpreting 119 trios. Genet Med. 2015 Oct; 17(10):774-81.  View on PubMed
  17. Zhu X, Need AC, Petrovski S, Goldstein DB. One gene, many neuropsychiatric disorders: lessons from Mendelian diseases. Nat Neurosci. 2014 Jun; 17(6):773-81.  View on PubMed
  18. Tan R, Wang Y, Kleinstein SE, Liu Y, Zhu X, Guo H, Jiang Q, Allen AS, Zhu M. An evaluation of copy number variation detection tools from whole-exome sequencing data. Hum Mutat. 2014 Jul; 35(7):899-907.  View on PubMed
  19. Liu Y, Li B, Tan R, Zhu X, Wang Y. A gradient-boosting approach for filtering de novo mutations in parent-offspring trios. Bioinformatics. 2014 Jul 01; 30(13):1830-6.  View on PubMed

Go to UCSF Profiles, powered by CTSI